NASDAQ:HCM HUTCHMED (HCM) Stock Price, News & Analysis $13.95 -0.45 (-3.12%) As of 12:06 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About HUTCHMED Stock (NASDAQ:HCM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HUTCHMED alerts:Sign Up Key Stats Today's Range$13.77▼$14.0450-Day Range$12.82▼$15.3852-Week Range$9.77▼$16.33Volume20,120 shsAverage Volume50,112 shsMarket Capitalization$2.43 billionP/E RatioN/ADividend YieldN/APrice Target$14.87Consensus RatingModerate Buy Company Overview HUTCHMED is a biopharmaceutical company focused on discovering, developing and commercializing medicines, particularly targeted therapies for cancer. Founded in 2000 as Hutchison China MediTech, the company adopted the HUTCHMED name in 2021. Its oncology medicines include fruquintinib, marketed in China as Elunate and in the United States and other markets as Fruzaqla through a partner; surufatinib, marketed in China as Sulanda; and savolitinib, marketed in China as Orpathys. The company also maintains a pipeline of investigational medicines for cancer and immunological diseases. Based in Hong Kong, HUTCHMED conducts research and development in China and works with commercial partners to bring its medicines to patients in China and other international markets.AI Generated. May Contain Errors. Read More HUTCHMED Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreHCM MarketRank™: 1.057385759825 of 5 starsHUTCHMED scored higher than 21% of companies evaluated by MarketBeat, and ranked 813th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingHUTCHMED has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for HUTCHMED is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageHUTCHMED has only been the subject of 3 research reports in the past 90 days.Read more about HUTCHMED's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings Growth-4.35% Earnings GrowthEarnings for HUTCHMED are expected to decrease by -4.35% in the coming year, from $0.23 to $0.22 per share.Price to Book Value per Share RatioHUTCHMED has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.16% of the float of HUTCHMED has been sold short.Short Interest Ratio / Days to CoverHUTCHMED has a short interest ratio ("days to cover") of 7.63.Change versus previous monthShort interest in HUTCHMED has recently increased by 3.91%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHUTCHMED does not currently pay a dividend.Dividend GrowthHUTCHMED does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.34 News SentimentHUTCHMED has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for HUTCHMED this week, compared to 2 articles on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, HUTCHMED insiders have not sold or bought any company stock.Percentage Held by Insiders3.60% of the stock of HUTCHMED is held by insiders.Percentage Held by Institutions8.82% of the stock of HUTCHMED is held by institutions.Read more about HUTCHMED's insider trading history. Receive HCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HCM Stock News HeadlinesHUTCHMED (AIM:HCM) Stock Looks Overvalued On Current EarningsNovember 17 at 5:50 PM | uk.finance.yahoo.comHUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®November 15 at 11:00 PM | globenewswire.comUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.November 18 at 1:00 AM | Profits Run (Ad)HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference TranscriptNovember 12, 2026 | seekingalpha.comHUTCHMED Sees $1 Billion Opportunity as Lung Cancer Combo Advances Toward ApprovalsNovember 8, 2026 | americanbankingnews.comHUTCHMED (China) (AIM:HCM) Extends Lung Cancer Filing Run As Undervalued View HoldsNovember 6, 2026 | uk.finance.yahoo.comHUTCHMED's Sovleplenib Gets FDA Orphan Drug Status For Autoimmune Hemolytic AnemiaNovember 5, 2026 | rttnews.comHUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic AnemiaNovember 4, 2026 | finance.yahoo.comSee More Headlines HCM Stock Analysis - Frequently Asked Questions How have HCM shares performed this year? HUTCHMED's stock was trading at $13.33 on January 1st, 2026. Since then, HCM shares have increased by 4.8% and is now trading at $13.9650. How were HUTCHMED's earnings last quarter? HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) announced its earnings results on Thursday, July, 30th. The company reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.15 by $0.10. The company had revenue of $139.14 million for the quarter, compared to analyst estimates of $304.16 million. Read the conference call transcript. When did HUTCHMED IPO? HUTCHMED (HCM) raised $100 million in an IPO on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities acted as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers. Who are HUTCHMED's major shareholders? Top institutional investors of HUTCHMED include State Street Corp (0.18%), AIA Group Ltd (0.15%), M&G PLC (0.14%) and Goldman Sachs Group Inc. (0.07%). How do I buy shares of HUTCHMED? Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HUTCHMED own? Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include NVIDIA (NVDA), NIO (NIO), Micron Technology (MU), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ) and Palo Alto Networks (PANW). Company Calendar Last Earnings7/30/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 HCM's financial health is in the Green zone, according to TradeSmith. HCM has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:HCM CIK1648257 Webwww.hutch-med.com Phone852-2121-3888Fax852-2128-1778Employees1,796Year Founded2000Price Target and Rating Average Price Target for HUTCHMED$14.87 High Price Target$17.00 Low Price Target$13.60 Potential Upside/Downside+6.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.06 Current Ratio5.64 Quick Ratio5.50 Sales & Book Value Annual Sales$548.51 million Price / Sales4.44 Cash Flow$2.55 per share Price / Cash Flow5.47 Book Value$7.17 per share Price / Book1.95Miscellaneous Outstanding Shares174,470,000Free Float168,186,000Market Cap$2.43 billion OptionableOptionable Beta0.30 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:HCM) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersGold Trades Near Record Highs: What It Means for MinersBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public co...Behind the Markets | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.